With plans to open in Athens, Istanbul and Sofia, Blue Longevity Clinic aims to embed personalized healthspan strategies into daily life.
Longevity clinics are becoming a more prominent feature of the global health landscape, evolving from niche, diagnostics-led services into more integrated platforms that combine personalized protocols, digital tools and continual care models. In Southeast Europe, where preventive healthcare remains a largely underdeveloped market, Blue Longevity Clinic is aiming to introduce a more integrated, lifestyle-based model of longevity care.
Announcing a €2 million (approx US$ 2.35m) raise led by Eleven Ventures, with participation from Sofia Angels Ventures and family offices, the company plans to open its first clinics this September in Athens, Istanbul and Sofia. Its model is striking in its vertical integration: functional diagnostic testing, in-house therapies, physician-led personalized protocols and a digital platform designed to reinforce behavioral change through microhabit formation.
Longevity.Technology: The rise of longevity clinics has, until now, tended to orbit high-income urban hubs and cater to early adopters with the means – and motivation – to invest in wearables, biomarker panels and full body scans; what Blue Longevity proposes is a shift from exclusivity to engagement – a model that embeds preventive care into the rhythm of everyday life rather than relegating it to a once-a-year indulgence. By targeting Southeast Europe – a region with high out-of-pocket health spending but relatively little in the way of personalized or preventive infrastructure – the company is not only filling a gap but attempting to build a market, one that may prove a strategic beachhead for medical tourism and digital health innovation alike.
The clinics are yet to open their doors, of course, and clinical efficacy, patient retention and scalability will be the real proof points – but the vision is notably global and the timing opportunistic. In an increasingly crowded field of diagnostics-driven ventures, Blue Longevity’s integration of continual care and digital microhabit formation might offer a more durable path to mainstreaming longevity medicine – establishments where the healthspan takeaways matter as much as the in-house menu.
A market in transition
Southeast Europe has long faced a conundrum in healthcare delivery: rising consumer expenditure – among the highest out-of-pocket rates in Europe – without a corresponding rise in access to preventive or longevity-focused care. Traditional hospitals in the region often lack both the clinical infrastructure and incentive to embrace functional medicine, leaving a gap between healthspan ambition and healthcare reality.
Blue Longevity believes this gap is its opportunity. Its founder and CEO, Ilian Grigorov, describes the offering not as a clinic in the traditional sense, but as a continual care partner: “We’re building a new kind of health centre – one that people don’t just visit once a year, but one that becomes part of their lifestyle. Longevity is not a single test or therapy – it’s a journey.”
From diagnostics to daily routines
The company’s approach places diagnostics at the entry point – including comprehensive metabolic, genetic, gut and brain biomarker analysis – followed by personalized protocols created by clinicians and supported by in-house therapies. These are bolstered by an AI-assisted longevity dashboard, with physician input to support dynamic risk assessment across multiple health domains.
In-clinic therapies are designed to reinforce these personalized interventions. Clients will have access to treatments including hyperbaric oxygen therapy, cryotherapy, intravenous infusion therapy, red light therapy and interval hypoxia-hyperoxia training (IHHT) – all selected for their potential impact on biological aging pathways such as glucose metabolism, mitochondrial performance, cardiovascular resilience and immune system balance.
The supporting digital infrastructure is built on the Fogg Behavior Model, using microhabit formation as a vehicle for sustained engagement. The Blue Longevity app integrates with wearables and medical devices to deliver hyperpersonalized coaching, track biomarker trends and improve protocol adherence over time.
Diagnostics span elite blood panels, VO₂ max testing, DNA methylation clocks, gut microbiome profiling, ECGs and musculoskeletal assessments – feeding into an AI-powered engine that flags actionable biomarkers and generates tailored longevity reports, which are reviewed and adjusted by physicians to ensure clinical relevance.
Why now – and why here?
According to Eleven Ventures, the time is right for Southeast Europe to assert itself within the broader longevity and wellness economy. “The transition from reactive sick care to proactive health care is no longer a trend, it’s a global shift,” said Valeri Petrov, Partner at Eleven Ventures. “We’ve been closely tracking this category and believe the SEE region has the potential to become a key hub for medical and longevity tourism.”
The region offers several advantages beyond cost competitiveness. With an educated urban population, increasing health awareness and relatively untapped private capital in healthcare delivery, there is room to innovate in ways that larger, more regulated systems may resist. Blue Longevity’s model – built to scale through its digital platform and AI infrastructure – may allow it to expand both within the region and beyond, without being bound entirely to brick-and-mortar clinical capacity.
Signals of sector maturation
From the investor perspective, Blue Longevity is also noteworthy for its operational credibility. Its founding team combines healthcare delivery experience with a track record of building scalable clinical ventures. This, coupled with a service structure that links diagnostics to engagement via habit formation and ongoing coaching, positions it closer to a healthtech-longevity hybrid than a traditional clinic chain.
“Longevity is becoming the new frontier of healthcare – no longer a privilege reserved for eccentric biohackers, reclusive yogis or billionaires,” said Milen Ivanov, Managing Partner at Sofia Angels Ventures. “The science is already advancing at scale, and this will become a trillion-euro industry that helps millions live longer, healthier lives. We believe in BL’s team and their ability to execute on their next healthcare venture, especially given the ripe timing for this mission.”
The clinics will begin operating this autumn, while the company also focuses on developing its proprietary app and AI diagnostics engine. Funds from the raise will support these build-outs, along with protocol development and expansion of the medical team.
Less spectacle, more substance
In a field often characterized by glossy dashboards and longevity promises that sometimes outpace data, Blue Longevity is positioning itself as both ambitious and grounded; it will need to navigate the clinical and regulatory complexity of operating across three countries, while also demonstrating that preventive protocols can retain engagement and show measurable outcomes.
Yet its timing is notable – health systems worldwide are contending with aging populations and rising chronic disease burdens, and models that incentivize long-term prevention will increasingly find favor with both policymakers and private payers. Blue Longevity may still be in the early stages, but its approach is in line with a shifting in tone for the sector – less spectacle, more substance and a measured attempt to embed longevity into everyday healthcare behavior.
